Compare PODD & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PODD | RDY |
|---|---|---|
| Founded | 2000 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 9.9B |
| IPO Year | 2007 | 2001 |
| Metric | PODD | RDY |
|---|---|---|
| Price | $145.42 | $14.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 5 |
| Target Price | ★ $178.57 | $14.40 |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 11-04-2026 | 10-23-2026 |
| Dividend Yield | N/A | ★ 0.44% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.69 | N/A |
| Revenue | ★ $2,708,100,000.00 | N/A |
| Revenue This Year | $22.02 | $4.57 |
| Revenue Next Year | $11.71 | $11.92 |
| P/E Ratio | $32.65 | ★ $18.67 |
| Revenue Growth | ★ 30.73 | N/A |
| 52 Week Low | $126.40 | $11.36 |
| 52 Week High | $354.88 | $15.67 |
| Indicator | PODD | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 47.66 | 67.91 |
| Support Level | $141.26 | $12.91 |
| Resistance Level | $153.33 | $15.08 |
| Average True Range (ATR) | 7.29 | 0.27 |
| MACD | -0.83 | -0.01 |
| Stochastic Oscillator | 9.08 | 73.02 |
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.